Technology/ Title:AXL Inhibitor as Anticancer Drug

Summary of Invention
1. A novel AXL kinase inhibitor with patentable chemical structure distinguished from known AXL inhibitors. The regular patent has been applied.

2. Good lead molecule significantly inhibits Gas6 ligand induced AKT phosphorylation in NSCLC and TNBC cell lines. The general in vitro potencies of our lead compound is superior to reference compound BGB324, which is currently in phase II clinical trial for treating lung cancer. In addition, this lead compound has good PK property and oral bioavailability.

Advantages when compared to the existing technologies
1. AXL inhibitor belonged to first-in-class medicine could interrupt tumor growth, blockade metastasis, overcome the drug resistance, potentiate chemotherapy, and enhance patient’s antitumor immunity. Therefore, AXL inhibitor is a novel medication for cancer treatment as well as cancer immunotherapy.

2. The chemical structure of lead compound is different from known AXL inhibitors. The regular patent has been applied. Moreover, the in vitro potencies of lead compound is superior to reference compound BGB324. Hence, the pre-candidate compound showed the potential for further clinical development.

Cancer with high AXL expression and unmet medical need